Elucidation of Carboxylesterase Mediated Pharmacokinetic Interactions between Irinotecan and Oroxylin A in Rats via Physiologically Based Pharmacokinetic Modeling.

[1]  A. Boddy,et al.  Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance , 2023, Cancer Chemotherapy and Pharmacology.

[2]  Z. Zuo,et al.  Inhibition of Radix Scutellariae flavones on carboxylesterase mediated activations of prodrugs. , 2022, Life sciences.

[3]  S. Heyward,et al.  Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation , 2021, Drug Metabolism and Disposition.

[4]  Christine M. Madla,et al.  Quantification of P-Glycoprotein in the Gastrointestinal Tract of Humans and Rodents: Methodology, Gut Region, Sex, and Species Matter , 2021, Molecular pharmaceutics.

[5]  S. Ben-Shabat,et al.  Computational Simulations to Guide Enzyme-Mediated Prodrug Activation , 2020, International journal of molecular sciences.

[6]  David B. Darr,et al.  Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy , 2020, Proceedings of the National Academy of Sciences.

[7]  Xijing Chen,et al.  Pharmacokinetics, tissue distribution and excretion study of Oroxylin A, Oroxylin A 7-O-glucuronide and Oroxylin A sodium sulfonate in rats after administration of Oroxylin A. , 2020, Fitoterapia.

[8]  Li Di,et al.  The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics , 2018, Current drug metabolism.

[9]  Kenji Mizuguchi,et al.  Predicting Fraction Unbound in Human Plasma from Chemical Structure: Improved Accuracy in the Low Value Ranges. , 2018, Molecular pharmaceutics.

[10]  Guangbo Ge,et al.  A Two-Photon Ratiometric Fluorescent Probe for Imaging Carboxylesterase 2 in Living Cells and Tissues. , 2015, ACS applied materials & interfaces.

[11]  L. Kuepfer,et al.  Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling , 2012, Drug Metabolism and Disposition.

[12]  A. Chalmers,et al.  Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets , 2011, British Journal of Cancer.

[13]  D. Yao,et al.  Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats , 2011, Acta Pharmacologica Sinica.

[14]  Shufeng Zhou,et al.  Herbal interactions with anticancer drugs: mechanistic and clinical considerations. , 2010, Current medicinal chemistry.

[15]  C. Klaassen,et al.  Nuclear receptor-mediated regulation of carboxylesterase expression and activity , 2010, Expert opinion on drug metabolism & toxicology.

[16]  Xinkun Wang,et al.  Regulation of Tissue-Specific Carboxylesterase Expression by Pregnane X Receptor and Constitutive Androstane Receptor , 2009, Drug Metabolism and Disposition.

[17]  Frederick W. Fraunfelder.  Ocular side effects associated with dietary supplements and herbal medicines. , 2005, Drugs of today.

[18]  C. Klaassen,et al.  Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. , 2004, Biochemical and biophysical research communications.

[19]  C. Klaassen,et al.  Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[20]  J. Robert,et al.  Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. , 1995, Pharmacology & therapeutics.